Kyowa Kirin and Swixx BioPharma Expand Access to POTELIGEO® for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe Kyowa Kirin International (KKI), a fully owned subsidiary of Kyowa…
Osta Therapeutics Expands Leadership Team with Two Industry Experts to Combat Antibiotic Resistance Osta Therapeutics Expands Leadership Team to Tackle Antibiotic Resistance Osta Therapeutics, a biotechnology company focused on developing…
Ethris Announces Promising Phase 1 Clinical Data for mRNA Therapeutic ETH47 in Asthma Treatment Ethris GmbH, a biotechnology pioneer in the development of next-generation RNA therapeutics and vaccines, has announced…
Owkin, a pioneering AI-biotech company dedicated to transforming drug discovery, development, and diagnostics through agentic AI, has announced the dosing of the first patient in its Phase I clinical trial…
Ferrer Earns Compliance Leader Verification™ for Exemplary Ethical and Responsible Corporate Practices Ferrer, a globally recognized pharmaceutical company, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere, an organization…
Virpax Pharmaceuticals Announces Public Offering Pricing to Fuel Drug Development and Innovation Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a forward-thinking preclinical-stage pharmaceutical company specializing in groundbreaking drug delivery systems for pain…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, has unveiled groundbreaking new data from the Phase III CALGB (Alliance) / SWOG 80702 study. These findings…
Bristol Myers Squibb Presents Results from CheckMate-8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in MSI-H/dMMR Metastatic Colorectal Cancer Bristol Myers Squibb (NYSE: BMY) has announced…
Exelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025 Exelixis Announces Promising Results from Phase 1b/2 STELLAR-001 Trial for Zanzalintinib in Metastatic Colorectal Cancer at…
Cancer Trial Data for FOG-001 to be Presented by Parabilis at ASCO GI Cancers Symposium Parabilis Medicines, formerly known as Fog Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing transformative…
Verastem Oncology Unveils Bold 2025 Priorities for RAS/MAPK Pathway Cancer Pipeline Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new treatments for RAS/MAPK pathway-driven cancers, has outlined its…
Vaccines Development: Vaxxas and CEPI Advance $4.8M Program for Needle-Free mRNA Vaxxas, a clinical-stage biotechnology company focused on commercializing its innovative high-density microarray patch (HD-MAP) vaccination platform, today announced that…